Platelet α2-adrenoreceptors, catecholamines, hemodynamic variables, and anxiety in panic patients and their asymptomatic relatives

Psychosomatic Medicine

Volumn 58, Issue 4, 1996, Pages 289-301

  Cameron, Oliver G ^a   Smith, Charles B ^a   Nesse, Randolph M ^a   Hill, Elizabeth M ^a   Hollingsworth, Peggie J ^a   Abelson, James A ^a   Hariharan, M ^a   Curtis, George C ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

adrenergic; catecholamines; familial; panic; platelet; treatment

Indexed keywords

ADRENALIN; ALPHA 2 ADRENERGIC RECEPTOR; ALPRAZOLAM; CATECHOLAMINE; CLONIDINE; FLUOXETINE; NORADRENALIN; TRICYCLIC ANTIDEPRESSANT AGENT; YOHIMBINE;

ADULT; ANXIETY NEUROSIS; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; COGNITIVE THERAPY; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HEART RATE; HEMODYNAMICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; PANIC; PRIORITY JOURNAL; RECEPTOR BINDING; RECUMBENCY; STANDING; SYMPTOMATOLOGY; THROMBOCYTE;

EID: 0029942160     PISSN: 00333174     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006842-199607000-00001     Document Type: Article

References (62)

1. Cameron OG: Adrenergic Dysfunction and Psychobiology. Washington, DC, American Psychiatric Press, 1994
2. Abelson JL, Cameron OG: Adrenergic dysfunction in anxiety disorders. In Cameron OG (ed), Adrenergic Dysfunction and Psychobiology. Washington, DC, American Psychiatric Press, 1994, 403-446
3. Maddock RJ, Carter CS, Magliozzi JR, et al: Evidence that decreased function of lymphocyte B adrenoreceptors reflects regulatory and adaptive processes in panic disorder with agoraphobia. Am J Psychiatry 150:1219-1225, 1993
4. Coplan JD, Papp LA, Martinez J, et al: Persistence of blunted growth hormone response to clonidine in fluoxetine-treated patients with panic disorder. Am J Psychiatry 152:619-622, 1995
5. Ko GN, Elsworth JD, Roth RH, et al: Panic-induced elevation of plasma MHPG levels in phobic-anxious patients: Effects of clonidine and imipramine. Arch Gen Psychiatry 40:425-430, 1983
6. Charney DS, Heninger GR, Breier A: Noradrenergic function in panic anxiety: Effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder. Arch Gen Psychiatry 41:751-763, 1984
7. Ballenger JC, Peterson GA, Laraia M, et al: A study of plasma catecholamines in agoraphobia and the relationship of serum tricyclic levels to treatment response. In Ballenger JC (ed), Biology of Agoraphobia. Washington, DC, American Psychiatric Press, 1984, 27-63
8. Nesse RM, Cameron OG, Curtis GC, et al: Adrenergic function in patients with panic anxiety. Arch Gen Psychiatry 41:771-776, 1984
9. Cameron OG, Smith CB, Hollingsworth PJ, et al: Platelet alpha2-adrenergic receptor binding and plasma catecholamines: Before and during imipramine treatment in patients with panic anxiety. Arch Gen Psychiatry 41:1144-1148, 1984
10. Cameron OG, Lee MA, Curtis GC, et al: Endocrine and physiological changes during "spontaneous" panic attacks. Psychoneuroendocrinology 17:321-331, 1987
11. Cameron OG, Smith CB, Lee MA, et al: Adrenergic status in anxiety disorders: Platelet alpha2-adrenergic receptor binding, blood pressure, pulse, and plasma catecholamines in panic and generalized anxiety disorder patients and in normal subjects. Biol Psychiatry 28:3-20, 1990
12. Stein MB, Tancer ME, Uhde TW: Heart rate and plasma norepinephrine responsivity to orthostatic challenge in anxiety disorders: Comparison of patients with panic disorder and social phobia and normal control subjects. Arch Gen Psychiatry 49:311-317, 1992
13. Stein MB, Asmundson GJG: Autonomic function in panic disorder: Cardiorespiratory and plasma catecholamine responsivity to multiple challenges of the autonomic nervous system. Biol Psychiatry 36:548-558, 1994
14. Braune S, Albus M, Frohler M, et al: Psychophysiological and biochemical changes in patients with panic attacks in a defined situational arousal. Eur Arch Psychiatry Clin Neurosci 244:86-92, 1994
15. Middleton HC, Ashby M, Robbins TW: Reduced plasma norepinephrine and abnormal heart rate variability in resting panic disorder patients. Biol Psychiatry 36:847-849, 1994
16. Cameron OG, Nesse RM: Systemic hormonal and physiological abnormalities in anxiety disorders. Psychoneuroendocrinology 13:287-307, 1988
17. Stahl SM: The human platelet: A diagnostic and research tool for the study of biogenic amines in psychiatric and neurologic disorders. Arch Gen Psychiatry 34:509-516, 1977
18. Campbell IC: Blood platelets and psychiatry. Br J Psychiatry 138:78-80, 1981
19. Albus M, Bondy B, Ackenheil M: Adrenergic receptors on blood cells: Relation to the pathophysiology of anxiety. Clin Neuropharmacol 9(Suppl4):359-361, 1986
20. Nutt DJ, Fraser S: Platelet binding studies in panic disorder. J Affect Disord 12:7-11, 1987
21. Charney DS, Innis RB, Duman RS, et al: Platelet alpha2-receptor binding and adenylate cyclase activity in panic disorder. Psychopharmacology 98:102-107, 1989
22. Grunhaus LJ, Cameron OG, Pande HC, et al: Comorbidity of panic disorder and major depressive disorder: Effects on platelet alpha2-adrenergic receptors. Acta Psychiatr Scand 81:216-219, 1990
23. Roy-Byrne PP, Uhde TW: Panic disorder and major depression: Biological relationships. Psychopharmacol Bull 21:551-554, 1985
24. 3H-rauwolscine binding in patients with panic attacks. Psychiatry Res 22:43-48, 1987
25. Freedman RR, Embury J, Migaly P, et al: Stress-induced desensitization of alpha2-adrenergic receptors in human platelets. Psychosom Med 52:624-630, 1990
26. Crowe RR: Molecular genetics and panic disorder: New approaches to an old problem. In Ballenger JC (ed), Neurobiology of Panic Disorder. New York, Wiley-Liss, 1990, 59-70
27. Goldstein RB, Weissman MM, Adams PB, et al: Psychiatric disorders in relatives of probands with panic disorder and/or major depression. Arch Gen Psychiatry 51:383-394, 1994
28. Kraemer HC, Gullion CM, Rush AJ, et al: Can state and trait variables be disentangled? A methodological framework for psychiatric disorders. Psychiatr Res 52:55-69, 1994
29. U'Pritchard DC: Biochemical characteristics and regulation of brain alpha2-adrenoreceptors. In Salama AI (ed), Presynaptic Modulation of Postsynaptic Receptors in Mental Disorders, Vol 430. New York, New York Academy of Sciences, 1984, 55-75
30. Leff P: The two-state model of receptor activation. Trends Pharmacol Sci 16:89-97, 1995
31. Spitzer RL, Williams JBW, Gibbon M, et al: User's Guide for the Structural Clinical Interview for DSM-III-R (SCID). Washington, DC, American Psychiatric Press, 1990
32. Hamilton M: The assessment of anxiety states by rating. Br J Med Psychol 32:50-55, 1959
33. Derogatis L: SCL-90-R: Administration, Scoring, and Procedures Manual II. Towson, MD, Clinical Psychiatric Research, 1983
34. Sheehan DV: The Anxiety Disease (Revised Paperback Edition). New York, Bantam Books, 1986
35. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62, 1960
36. Insel PA, Motulsky HJ: Physiologic and pharmacologic regulation of adrenergic receptors. In Insel PA (ed), Adrenergic Receptors in Man. New York, Marcel Dekker, 1987, 201-236
37. 3H] yohimbine competitive inhibition by antidepressant drugs. Eur J Pharmacol 74:329-341, 1981
38. Cameron OG, Gunsher S, Hariharan M: Venous plasma epinephrine levels and the symptoms of stress. Psychosom Med 52:411-424, 1990
39. Cameron OG, Thyer BA, Nesse RM, et al: Symptom profiles of patients with DSM-III anxiety disorders. Am J Psychiatry 143:1132-1137, 1986
40. Hays WL: Statistics. New York, Holt, Rinehart and Winston, 1981, 289-296 and 349-350
41. Ross RJ, Zavadil AP, Calil HM, et al: Effects of desmethylimipramine on plasma norepinephrine, pulse, and blood pressure. Clin Pharmacol Ther 33:429-437, 1983
42. Veith RC, Raskind MA, Barnes RF, et al: Tricyclic antidepressants and supine, standing, and exercise plasma norepinephrine levels. Clin Pharmacol Ther 33:763-769, 1983
43. Propping P, Friedl W: Genetic control of adrenergic receptors on human platelets: A twin study. Hum Genet 64:105-109, 1983
44. Lima DR, Turner P: Propranolol increases reduced beta-receptor function in severely anxious patients. Lancet 2:1505, 1983
45. Aronson TA, Carasiti I, McBane D, et al: Biological correlates of lactate sensitivity in panic disorder. Biol Psychiatry 26: 463-477, 1989
46. Brown SL, Charney DS, Woods SW, et al: Lymphocyte beta-adrenergic receptor binding in panic disorder. Psychopharmacology 94:24-28, 1988
47. Huzel LL, Delaney SM, Stein MB: Lymphocyte beta-adrenergic receptors in panic disorder: Findings with a highly selective ligand and relationship to clinical parameters. Anxiety Disord 7:349-357, 1993
48. Jones SB, Bylund DB, Rieser CA, et al: Alpha 2-adrenergic receptor binding in human platelets: Alterations during the menstrual cycle. Clin Pharmacol Ther 34:90-96, 1983
49. O'Malley K, Docherty JR, Kelly JG: Adrenoceptor status and cardiovascular function in ageing. J Hypertens 6(Suppl):S59-S62, 1988
50. Motulsky HJ, O'Connor DT, Insel PA: Platelet alpha 2-adrenergic receptors in treated and untreated essential hypertension. Clin Sci 64:265-272, 1983
51. Reimann IW, Britzelmeier C, Bieck PR: Intra-subject variability of platelet alpha 2-adrenoceptor binding sites in healthy volunteers. Methods Find Exp Clin Pharmacol 9:677-683, 1987
52. Stowell LI, McIntosh CJ, Cooke R, et al: Adrenoceptor and imipramine receptor binding during the menstrual cycle. Acta Psychiatr Scand 78:366-368, 1988
53. Sundaresan PR, Madan MK, Kelvie SL, et al: Platelet alpha-2 adrenoceptors and the menstrual cycle. Clin Pharmacol Ther 37:337-342, 1985
54. Rosen SG, Berk MA, Popp DA, et al: Beta 2- and alpha 2-adrenergic receptors and receptor coupling to adenylate cyclase in human mononuclear leukocytes and platelets in relation to physiological variations of sex steroids. J Clin Endocrinol Metab 58:1068-1076, 1984
55. Theodorou AE, Mistry H, Davies SL, et al: Platelet alpha 2-adrenoceptor binding and functioning during the menstrual cycle. J Psychiatr Res 21:163-169, 1987
56. Bursztyn M, Bresnahan M, Gavras I, et al: Effect of aging on vasopressin, catecholamines, and alpha 2-adrenergic receptors. J Am Geriatr Soc 38:628-632, 1990
57. Wang ZW, Crowe RR, Noyes R: Adrenergic receptor genes as candidate genes for panic disorder: A linkage study. Am J Psychiatry 149:470-474, 1992
58. Mills PJ, Dimsdale JE: The promise of receptor studies in psychophysiologic research. Psychosom Med 50:555-566, 1988
59. Mills PJ, Dimsdale JE: The promise of adrenergic receptor studies in psychophysiologic research II: Applications, limitations, and progress. Psychosom Med 55:448-457, 1993
60. Amsterdam JD, Maislin G, Skolnick B, et al: Multiple hormone responses to clonidine administration in depressed patients and healthy volunteers. Biol Psychiatry 26:265-278, 1989
61. Schittecatte M, Charles G, Machowski R, et al: Effects of gender and diagnosis on growth hormone response to clonidine for major depression: A large-scale multicenter study. Am J Psychiatry 151:216-220, 1994
62. Piletz JE, Halaris A, Ernsberger PR: Psychopharmacology of imidazoline and alpha2-adrenergic receptors: Implications for depression. Crit Rev Neurobiol 9:29-66, 1994